Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.34 |
| ▸ | KDM4A | O75164 | 12/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710315 | 0.84 | FAAH (0.42) | — | |
| SCHEMBL9128093 | 0.84 | FAAH (0.42) | — | |
| SCHEMBL7707564 | 0.81 | FAAH (0.40) | ALDH1A1 | |
| SCHEMBL19856505 | 0.80 | TSHR (0.34) | ALDH1A1TSHRDNM1KDM4AKDM4C | |
| SCHEMBL28669002 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRTRPV1 | |
| SCHEMBL8495229 | 0.77 | TSHR (0.36) | TSHRTRPV1 | |
| SCHEMBL6517414 | 0.75 | TSHR (0.37) | ALDH1A1TSHRTRPV1 | |
| SCHEMBL26315 | 0.70 | TSHR (0.40) | ALDH1A1TSHRUSP2 | |
| SCHEMBL20179472 | 0.69 | ALDH1A1 (0.40) | ALDH1A1TSHRPAOXUSP2DNM1 | |
| SCHEMBL19545894 | 0.69 | ALDH1A1 (0.40) | ALDH1A1TSHRPAOXUSP2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10266476-B2 | (Meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-20180118658-A1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3281933-A1 | (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118658-A1 | (METH)ACRYLATE MANUFACTURING METHOD | MMAB, PAM, MAT2B | ALDH1A1 264/4885TSHR 1174/4885TRPV1 4545/4885 |
| US-10266476-B2 | (Meth)acrylate manufacturing method | MMAB, PAM, MAT2B | ALDH1A1 264/4885TSHR 1174/4885TRPV1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.